BioSpace News Archive

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the appointment of Dr. Jesse McCool to Chief Executive Officer.

Opthea Limited, a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient dosing and all follow-up week 12 patient visits in the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept for treatment of diabetic macular edema.

Results from a sub-study of 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device, of 159 randomized patients who received either Mesoblast’s allogeneic mesenchymal precursor cell product candidate Revascor® or saline, were presented on March 28 at the American College of Cardiology Virtual Scientific Sessions.

Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic™ medicines, provided an update on its business operations and expected clinical activities as a result of the COVID-19 pandemic.

Taltz is the first and only IL-17A antagonist approved to treat this population

Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion, a liquid bendamustine injection with a 10-minute administration time, in Japan.

Myriad Genetics, Inc. announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis® Diagnostic System to be used as a companion diagnostic to help to identify people with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor, Lynparza®, subject to regulatory approval.

Microbix Biosystems Inc. announces the creation, verification, and imminent commercial availability of a quality assessment product to help ensure the accuracy of COVID-19 disease testing..

BioCryst Pharmaceuticals, Inc. announced that the European Medicines Agency has validated its marketing authorization application submission for approval of oral, once-daily berotralstat for the prevention of hereditary angioedema attacks..

Sedana Medical AB announced that the company sees increased demand for AnaConDa as a result of the Covid-19 pandemic and so far, has had no significant supply chain disruptions.